医学
比伐卢定
肝素
心脏病学
内科学
心肌梗塞
经皮冠状动脉介入治疗
作者
Gregg W. Stone,Marco Valgimigli,David Erlinge,Yaling Han,Philippe Gabríel Steg,Rod Stables,Enrico Frigoli,Stefan James,Yi Li,Patrick Goldstein,Roxana Mehran,Ghazaleh Mehdipoor,Aaron Crowley,Shmuel Chen,Björn Redfors,Clayton Snyder,Zhipeng Zhou,Behnood Bikdeli
标识
DOI:10.1016/j.jacc.2024.07.045
摘要
In the BRIGHT-4 (Bivalirudin With Prolonged Full-Dose Infusion During Primary PCI Versus Heparin Trial-4), anticoagulation with bivalirudin plus a 2- to 4-hour high-dose infusion after percutaneous coronary intervention (PCI) reduced all-cause mortality and bleeding without increasing reinfarction or stent thrombosis compared with heparin alone in patients with ST-segment elevation myocardial infarction (STEMI). These findings require external validation.
科研通智能强力驱动
Strongly Powered by AbleSci AI